maintenance therapy following treatment for amyloidosis
Published 4 years ago • 118 plays • Length 1:02Download video MP4
Download video MP3
Similar videos
-
1:48
do all patients require maintenance therapy following allosct?
-
1:41
defining the optimal duration of treatment with daracybord & dara maintenance in al amyloidosis
-
1:45
real-world data in guiding amyloidosis treatment
-
1:59
topics of interest in mds: the role of maintenance therapy, immune checkpoints & ven-aza in hr-mds
-
1:19
astx727 a molecularly-targeted agent as personalized maintenance therapy in patients with aml
-
0:43
the use of oral ixazomib maintenance following autosct in patients with ndmm
-
2:22
the need for novel agents to treat patients with mcl who have relapsed after targeted therapy
-
1:59
assessing if a patient with dlbcl is responding to treatment using pet-ct and novel assays
-
2:43
the importance of the mdt to provide adequate treatment and care to patients with amyloidosis
-
8:21
quazar aml-001: a new standard for aml maintenance therapy
-
1:44
improving maintenance therapy in aml: exploring the role of idh inhibitors
-
0:49
targeting deposits in amyloidosis
-
1:33
sorafenib as maintenance therapy for patients with transplant-ineligible or post-allosct aml
-
14:43
current research into post-allosct maintenance therapy in aml
-
1:33
the use of gilteritinib in post-transplant maintenance for aml with flt3-itd
-
1:57
insights into the treatment of patients with flt3-mutated aml & the role of maintenance therapy
-
2:49
maintenance therapy in aml: agents under investigation and future outlooks
-
5:16
the evolution of al amyloidosis therapy